Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 22;8(10):1523.
doi: 10.3390/jcm8101523.

Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease

Françoise Bernaudin  1
Affiliations
Review

Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease

Françoise Bernaudin. J Clin Med. .

Abstract

Considering the progress made in the management of sickle cell disease during the past 30 years, along with the excellent results obtained with hematopoietic stem cell transplantation (SCT), it is important to reexamine why, who, when and how to recommend allogeneic SCT in children with sickle cell disease. While sickle cell disease has a low risk of death in children and a high risk for morbidity during aging, SCT carries an early risk of death, graft-vs-host disease and infertility. Nevertheless, SCT offers at least 95% chance of cure with low risk of chronic graft-vs-host disease when a matched-sibling donor is available and the risks of infertility can be reduced by ovarian, sperm or testis cryopreservation. Thus, all available therapies such as hydroxyurea, transfusions and SCT should be presented to the parents, providers, and affected children and discussed with them from infancy. Furthermore, the use of these therapies should be adjusted to the severity of the disease and to local availabilities in order to choose the treatment offering the best benefit/risk ratio.

Keywords: acute-chest syndrome; cerebral silent infarct; cerebral vasculopathy; hematopoïetic stem cell transplantation; hydroxyurea; sickle cell anemia; sickle cell disease; stroke; transfusion; vaso-occlusive crisis.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Difference between a transfused sickle-cell anemia (SCA)-patient who has a double population of sickle SS cells and transfused normal AA red cells and a transplanted patient who has only normal red blood cells as the donor (AS or AA) and no more sickle cells.
Figure 2
Figure 2
When to recommend SCT in children with sickle cell disease?
Figure 3
Figure 3
Indications of the different treatments: hydroxyurea, chronic transfusion and. type of SCT to recommend in children with cerebral vasculopathy. Abbreviations: HU = hydroxyurea, MSD = matched-sibling donor, SCT = stem cell transplantation, Haplo = related haplo-identical, URD = unrelated stem cell-transplantation.
Figure 4
Figure 4
Indications of the different treatments: hydroxyurea, chronic transfusion and. which kind of stem cell transplantation to propose in children with frequent vaso-occlusives or recurrent acute chest syndrome Abbreviations: VOC = vaso-occlusive crisis, ACS = acute-chest syndrome, HU = hydroxyurea, MSD = matched-sibling donor, SCT = stem cell transplantation, Haplo = related haplo-identical, URD = unrelated stem cell-transplantation, MAC = myeloablative conditioning.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Piel F.B., Hay S.I., Gupta S., Weatherall D.J., Williams T.N. Global burden of sickle cell anaemia in children under five, 2010–2050: Modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10:e1001484. doi: 10.1371/journal.pmed.1001484. - DOI - PMC - PubMed
    1. Piel F.B., Steinberg M.H., Rees D.C. Sickle Cell Disease. N. Engl. J. Med. 2017;376:1561–1573. doi: 10.1056/NEJMra1510865. - DOI - PubMed
    1. Ware R.E., de Montalembert M., Tshilolo L., Abboud M.R. Sickle cell disease. Lancet. 2017;390:311–323. doi: 10.1016/S0140-6736(17)30193-9. - DOI - PubMed
    1. Gaston M.H., Verter J.I., Woods G., Pegelow C., Kelleher J., Presbury G., Zarkowsky H., Vichinsky E., Iyer R., Lobel J.S., et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N. Engl. J. Med. 1986;314:1593–1599. doi: 10.1056/NEJM198606193142501. - DOI - PubMed
    1. Adamkiewicz T.V., Silk B.J., Howgate J Baughman W., Strayhorn G., Sullivan K., Farley M.M. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121:562–569. doi: 10.1542/peds.2007-0018. - DOI - PubMed

LinkOut - more resources